ReviewFrontiers in pharmacology2021
Rituximab Therapy for Primary Sjögren's Syndrome.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Beyond systemic lupus erythematosus: a systematic review on the use of belimumab in other connective tissue diseases and vasculitides.Clinical rheumatology · 2026Pooled it
- Safety and effectiveness of rituximab therapy in Sjögren's disease: a PORTRESS - the Portuguese registry of Sjögren's disease-based study.Clinical rheumatology · 2026Observational
- Immunological profiling of rheumatoid factor-positive primary Sjögren's syndrome by single-cell RNA sequencing.Frontiers in immunology · 2026Article
- Molecular hydrogen is associated with immunophenotypic modulation and changes in T-cell exhaustion markers in refractory primary Sjögren's syndrome-associated interstitial lung disease: A case report.SAGE open medical case reports · 2026Article
- [Clinical efficacy and safety of rituximab in treating renal injury in primary Sjögren syndrome].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Regulatory T cell therapy for Sjögren's disease: From pathogenesis to targeted treatment.Journal of translational autoimmunity · 2025Review
- Efficacy of early rituximab treatment in primary Sjögren's syndrome: a systematic review and meta-analysis.Journal of rheumatic diseases · 2025Article
- Machine learning approach to single cell transcriptomic analysis of Sjogren's disease reveals altered activation states of B and T lymphocytes.Journal of autoimmunity · 2025Article
- Review
- Case Report: A case of membranous nephropathy associated with primary Sjögren's syndrome treated with telitacicept.Frontiers in immunology · 2025Article
- Article
- Review
- Treatment of non-systemic Sjögren's syndrome: Potential prevention of systematization with immunosuppressant agent/biotherapy.Journal of translational autoimmunity · 2024Article
- B-Cell Receptor Repertoire: Recent Advances in Autoimmune Diseases.Clinical reviews in allergy & immunology · 2024Review
- Emerging biologic frontiers for Sjogren's syndrome: Unveiling novel approaches with emphasis on extra glandular pathology.Frontiers in pharmacology · 2024Review
- Subpopulation dynamics of T and B lymphocytes in Sjögren's syndrome: implications for disease activity and treatment.Frontiers in immunology · 2024Review
- Switching from rituximab originator to GP2013 or CT-P10 biosimilars in autoimmune rheumatic diseases: drug retention rate and safety data from a multicentric retrospective cohort.Therapeutic advances in musculoskeletal disease · 2024Article
- B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study.Clinical and experimental medicine · 2023Observational
- Emerging treatment for Sjögren's disease: a review of recent phase II and III trials.Expert opinion on emerging drugs · 2023Review
- Causal associations of Sjögren's syndrome with cancers: a two-sample Mendelian randomization study.Arthritis research & therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary Sjögren's syndrome (pSS) is a systemic autoimmune diseases of the connective tissues, characteristic of the presentation of keratoconjunctivitis sicca and xerostomia. A cardinal pathogenetic feature of SS is B-cell hyperactivity, which has invited efforts on optimal B-cell targeted therapy, whereas conventional corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are restricted to symptomatic relief. As per the first EULAR recommendation for pSS patients published in 2020, regimens with monoclonal antibodies targeting B cells may be initiated in patients with severe, refractory systemic disease, notably rituximab (RTX), a mouse-derived monoclonal antibody that targets CD20 antigen and contributes to B-cell depletion. Nonetheless, the data available from clinical trials with RTX are often controversial. Despite the lack of promising results from two large RCTs, several positive clinical efficacies were demonstrated. This current review addressed the efficacy and safety of clinical trials available and elucidated the potential of RTX on the immune system, especially B and T cells. Furthermore, plausible explanations for the discrepancy in clinical data were also presented.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.